NCT07415018 Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
| NCT ID | NCT07415018 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Leptomeningeal Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-06-10 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-06-10 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Eligibility Criteria
Inclusion Criteria: * Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors. * Participants \> 18 years of age. * Participants are able to consent. Exclusion Criteria: * Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD. * Participants with implantable devices that can not be scanned with MR safe mode for participant safety. * Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus Pediatric participants \< 18 years of age.
Contact & Investigator
Rami Eldaya, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07415018 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leptomeningeal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07415018 currently recruiting?
Yes, NCT07415018 is actively recruiting participants. Contact the research team at reldaya@mdanderson.org for enrollment information.
Where is the NCT07415018 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07415018 clinical trial?
NCT07415018 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Rami Eldaya, MD at M.D. Anderson Cancer Center. The trial plans to enroll 40 participants.